Margetuximab Plus Tucatinib and Capecitabine in HER2-positive Metastatic Breast Cancer
Status:
Not yet recruiting
Trial end date:
2024-10-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, open-label, single-arm, phase II clinical trial to evaluate the
efficacy and safety of margetuximab in combination with tucatinib and capecitabine in
patients with HER2-positive metastatic breast cancer.